170 related articles for article (PubMed ID: 7282520)
1. Digoxin disposition in obesity: clinical pharmacokinetic investigation.
Abernethy DR; Greenblatt DJ; Smith TW
Am Heart J; 1981 Oct; 102(4):740-4. PubMed ID: 7282520
[TBL] [Abstract][Full Text] [Related]
2. Cimetidine disposition in obesity.
Abernethy DR; Greenblatt DJ; Matlis R; Gugler R
Am J Gastroenterol; 1984 Feb; 79(2):91-4. PubMed ID: 6364798
[TBL] [Abstract][Full Text] [Related]
3. Obesity effects on nitrazepam disposition.
Abernethy DR; Greenblatt DJ; Locniskar A; Ochs HR; Harmatz JS; Shader RI
Br J Clin Pharmacol; 1986 Nov; 22(5):551-7. PubMed ID: 3790401
[TBL] [Abstract][Full Text] [Related]
4. Theophylline disposition in obesity.
Gal P; Jusko WJ; Yurchak AM; Franklin BA
Clin Pharmacol Ther; 1978 Apr; 23(4):438-44. PubMed ID: 630791
[TBL] [Abstract][Full Text] [Related]
5. Caffeine disposition in obesity.
Abernethy DR; Todd EL; Schwartz JB
Br J Clin Pharmacol; 1985 Jul; 20(1):61-6. PubMed ID: 4027137
[TBL] [Abstract][Full Text] [Related]
6. Phenytoin disposition in obesity. Determination of loading dose.
Abernethy DR; Greenblatt DJ
Arch Neurol; 1985 May; 42(5):468-71. PubMed ID: 3994563
[TBL] [Abstract][Full Text] [Related]
7. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.
Lind MJ; Margison JM; Cerny T; Thatcher N; Wilkinson PM
Cancer Chemother Pharmacol; 1989; 25(2):139-42. PubMed ID: 2557169
[TBL] [Abstract][Full Text] [Related]
8. Carbamazepine pharmacokinetics in obese and lean subjects.
Caraco Y; Zylber-Katz E; Berry EM; Levy M
Ann Pharmacother; 1995 Sep; 29(9):843-7. PubMed ID: 8547729
[TBL] [Abstract][Full Text] [Related]
9. Lidocaine disposition in obesity.
Abernethy DR; Greenblatt DJ
Am J Cardiol; 1984 Apr; 53(8):1183-6. PubMed ID: 6702701
[TBL] [Abstract][Full Text] [Related]
10. The effect of obesity on apparent volume of distribution of theophylline.
Rohrbaugh TM; Danish M; Ragni MC; Yaffe SJ
Pediatr Pharmacol (New York); 1982; 2(1):75-83. PubMed ID: 7110759
[TBL] [Abstract][Full Text] [Related]
11. Dose-independent pharmacokinetics of digoxin in humans.
Ochs HR; Greenblatt DJ; Bodem G; Harmatz JS
Am Heart J; 1978 Oct; 96(4):507-11. PubMed ID: 358815
[TBL] [Abstract][Full Text] [Related]
12. Obesity, sex, and acetaminophen disposition.
Abernethy DR; Divoll M; Greenblatt DJ; Ameer B
Clin Pharmacol Ther; 1982 Jun; 31(6):783-90. PubMed ID: 7075126
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of digoxin in low-birth-weight infants.
Collins-Nakai RL; Schiff D; Ng PK
Dev Pharmacol Ther; 1982; 5(1-2):86-97. PubMed ID: 7151640
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).
Abernethy DR; Greenblatt DJ; Divoll M; Shader RI
J Pharm Sci; 1982 Aug; 71(8):942-4. PubMed ID: 6811726
[TBL] [Abstract][Full Text] [Related]
15. Procainamide disposition in obesity.
Christoff PB; Conti DR; Naylor C; Jusko WJ
Drug Intell Clin Pharm; 1983; 17(7-8):516-22. PubMed ID: 6191939
[TBL] [Abstract][Full Text] [Related]
16. Digoxin-quinidine interaction Pharmacokinetic evaluation.
Hager WD; Fenster P; Mayersohn M; Perrier D; Graves P; Marcus FI; Goldman S
N Engl J Med; 1979 May; 300(22):1238-41. PubMed ID: 431681
[TBL] [Abstract][Full Text] [Related]
17. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen.
Abernethy DR; Greenblatt DJ; Divoll M; Shader RI
J Lab Clin Med; 1983 Jun; 101(6):873-80. PubMed ID: 6133901
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin clearance in the obese.
Rodvold KA; Rushing DA; Tewksbury DA
J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of digoxin in sheep: limitations of the use of biological half-life for interspecies extrapolation.
Dix LP; Bai SA; Rogers RA; Anderson DL; Riviere JE
Am J Vet Res; 1985 Feb; 46(2):470-2. PubMed ID: 3994115
[TBL] [Abstract][Full Text] [Related]
20. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
